Show simple item record

dc.contributor.authorSophan, Sam
dc.contributor.authormeng, Chhour Y.
dc.contributor.authorPean, Polidy
dc.contributor.authorHarwell, Joseph
dc.contributor.authorHutton, Elizabeth
dc.contributor.authorTrzmielina, Sonia
dc.contributor.authorSomasundaran, Mohan
dc.contributor.authorLuzuriaga, Katherine
dc.contributor.authorPugatch, David
dc.date2022-08-11T08:10:12.000
dc.date.accessioned2022-08-23T16:59:00Z
dc.date.available2022-08-23T16:59:00Z
dc.date.issued2010-01-01
dc.date.submitted2012-05-01
dc.identifier.citationSoutheast Asian J Trop Med Public Health. 2010 Jan;41(1):126-37.
dc.identifier.issn0125-1562 (Linking)
dc.identifier.pmid20578491
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43486
dc.description.abstractThis observational cohort study was conducted among HIV-infected, antiretroviral therapy (ART) naive children in Phnom Penh, Cambodia, to evaluate the feasibility and efficacy of highly active antiretroviral therapy (HAART) delivered using a modified directly observed therapy (MDOT) protocol. From August 2004 to March 2006, 26 children were enrolled and started on a first-line HAART regimen, which was continued for 18 months. The study included a directly observed therapy phase (months 1-3) and a medication self-administration phase (months 4-18). CD4 percentage (CD4%) and HIV-1 RNA plasma viral load (PVL) were measured at baseline and at months 6, 12, and 18. At baseline, the median age was 5.5 years (range: 13 months-12 years), the median CD4% was 4, and the median PVL was 7.5x10(5) copies/ml. At 18 months, 23 (88%) children were alive and participating in the study. Of these children, 20 (87%) had a PVL /ml and 12 (52%) had PVL < 50 copies/ml. The median CD4% increased to 23, while the median change in height-for-weight z-score was 0.64. Genotypic resistance typing in 2 children with PVL > 400 copies/ml at 18 months demonstrated mutations associated with resistance to lamivudine (M184V) and non-nucleoside reverse transcriptase inhibitors (Y181C and G190A). The virologic and immunologic outcomes achieved in this study compare favorably with those reported by other pediatric HIV treatment programs worldwide. The study results suggest that MDOT may be effective for HAART administration in limited-resource settings like Cambodia.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=20578491&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981867/pdf/nihms249845.pdf
dc.subjectAdolescent
dc.subjectAnti-HIV Agents
dc.subjectAntiretroviral Therapy, Highly Active
dc.subjectCD4 Lymphocyte Count
dc.subjectCambodia
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectCohort Studies
dc.subjectDirectly Observed Therapy
dc.subjectDrug Resistance, Viral
dc.subjectFemale
dc.subjectHIV Infections
dc.subjectHIV-1
dc.subjectHuman Growth Hormone
dc.subjectHumans
dc.subjectInfant
dc.subjectLamivudine
dc.subjectMale
dc.subjectNevirapine
dc.subjectPilot Projects
dc.subjectStavudine
dc.subjectTreatment Outcome
dc.subjectImmunology and Infectious Disease
dc.subjectPediatrics
dc.subjectVirus Diseases
dc.titleVirologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART)
dc.typeJournal Article
dc.source.journaltitleThe Southeast Asian journal of tropical medicine and public health
dc.source.volume41
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_immunology/67
dc.identifier.contextkey2814398
html.description.abstract<p>This observational cohort study was conducted among HIV-infected, antiretroviral therapy (ART) naive children in Phnom Penh, Cambodia, to evaluate the feasibility and efficacy of highly active antiretroviral therapy (HAART) delivered using a modified directly observed therapy (MDOT) protocol. From August 2004 to March 2006, 26 children were enrolled and started on a first-line HAART regimen, which was continued for 18 months. The study included a directly observed therapy phase (months 1-3) and a medication self-administration phase (months 4-18). CD4 percentage (CD4%) and HIV-1 RNA plasma viral load (PVL) were measured at baseline and at months 6, 12, and 18. At baseline, the median age was 5.5 years (range: 13 months-12 years), the median CD4% was 4, and the median PVL was 7.5x10(5) copies/ml. At 18 months, 23 (88%) children were alive and participating in the study. Of these children, 20 (87%) had a PVL /ml and 12 (52%) had PVL < 50 copies/ml. The median CD4% increased to 23, while the median change in height-for-weight z-score was 0.64. Genotypic resistance typing in 2 children with PVL > 400 copies/ml at 18 months demonstrated mutations associated with resistance to lamivudine (M184V) and non-nucleoside reverse transcriptase inhibitors (Y181C and G190A). The virologic and immunologic outcomes achieved in this study compare favorably with those reported by other pediatric HIV treatment programs worldwide. The study results suggest that MDOT may be effective for HAART administration in limited-resource settings like Cambodia.</p>
dc.identifier.submissionpathpeds_immunology/67
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages126-37


This item appears in the following Collection(s)

Show simple item record